Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, shares an insight into current and upcoming treatment focuses in the chronic lymphocytic leukemia (CLL) field. This includes an emphasis on optimizing combination strategies, both for newly diagnosed and relapsed/refractory patients, as well as increasing the use of measurable residual disease data to drive treatment decisions. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.